Pulsed dose rate brachytherapy – description of a method and a review of clinical applications  by Skowronek, Janusz et al.
Skowronek et al.: Pulsed dose rate … 
Rep. Pract. Oncol. Radiother. 6 (4) 2001  
PULSED DOSE RATE BRACHYTHERAPY – DESCRIPTION 
OF A METHOD AND A REVIEW OF CLINICAL APPLI-
CATIONS  
 
Janusz Skowronek1, Grzegorz Zwierzchowski2, Tomasz Piotrowski2 
 
1I Department of Radiotherapy, 2Department of Medical Physics, Greatpoland Cancer Centre, Garbary 15, 
61-866 Poznań, Poland 
 
Received August 28th, 2001; received in a revised form January 8th, 2002; accepted January 14th, 
2002 
 
SUMMARY 
 
   Pulsed Dose Rate (PDR) treatment is a new brachytherapy modality that combines physical 
advantages of high-dose-rate (HDR) technology (isodose optimization and radiation safety) with 
radiobiological advantages of low-dose-rate (LDR) brachytherapy.  
   Pulsed brachytherapy uses a stronger radiation source than that employed in LDR brachytherapy 
and provides a series of short 10 to 30 minutes long exposures every hour amounting 
to approximately the same total dose in the same overall as that administered in the LDR.  
   Modern afterloading equipment offers some advantages over interstitial or intracavitary insertion 
of separate needles, tubes, seeds or wires. Isodose volumes in tissue can be created flexibly 
by a combination of careful positioning of the catheter and by adjusting the dwell times of the com-
puterized stepping source. Automatic removal of radiation sources into a shielded safe eliminates 
radiation exposures to staff and visitors. Radiation exposure is also eliminated to the staff who pre-
viously loaded and unloaded a large variety of radioactive sources into the catheters, ovoids, tubes etc. 
   This review, based on summarized clinical investigations, analyses the feasibility, differences 
between methods of brachytherapy and preliminary clinical applications of PDR brachytherapy.    
 
Key words: PDR brachytherapy, method of treatment, clinical applications. 
 
INTRODUCTION 
 
   The efficacy of brachytherapy, as com-
pared with the efficacy of external beam 
alone, is attributable to the ability of ra-
dioactive implants to deliver a higher 
concentrated radiation dose more 
precisely to tissues, which contributes 
to improved local control, provided that 
the tissue is clinically delimitable and 
accessible. At the same time, the surroun-
ding healthy tissues are spared irradiation. 
In contrast to external-beam irradiation, 
brachytherapy is invasive, requiring 
insertion of site-specific applicators under 
sedation or anaesthesia. The surgeon who 
is sometimes involved in these pro-
cedures, particularly if laparotomy or cra-
niotomy is required for the insertion 
of applicators, or if tumour resection 
is required prior to applicator insertion, 
should be aware of the indications 
for brachytherapy and the associated 
techniques [1,2,3].  
   Brachytherapy, with modern afterloading 
equipment, offers three major advantages 
over interstitial or intracavitary insertion 
of separate needles, tubes, seeds or wires:  
(1) Isodose volumes in tissue can be cre-
ated at will by a combination of careful 
placement of the catheter and adjust-
ment of the dwell times of the com-
puterized stepping source. This process 
is usually called “dose optimization”. 
(2) Automatic removal of radiation sources 
into a shielded safe whenever some-
body enters the room eliminates 
radiation exposures to staff and visitors. 
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(3) Radiation exposure is also eliminated to 
the staff who previously loaded and 
unloaded a large variety of radioactive 
sources into catheters, ovoids, tubes 
etc [1,4,5,6,7]. 
   Low Dose Rate (LDR) remote after-
loading systems certainly give radiation 
protection, but do not provide as much 
flexibility in the design of alter native 
isodose volumes as that obtained with 
higher dose rate sources with adjustable 
stepping positions and dwell times.  
   At the other end of the spectrum of bra-
chytherapy methods is the use of High 
Dose Rate (HDR) afterloading with a sin-
gle source of 192 Ir moved by computer 
to a series of dwell positions. In that case 
the choice of isodose volume is very 
flexible. Large doses can be given within 
a few minutes. Sources of that kind require 
well-shielded bunkers similar to linear 
accelerator rooms.   
   One radiobiological disadvantage 
in the use of such high dose rates, 
of 1-3 Gy/min (greater ratio of late tissue 
effects), can in practice be overcome 
by careful placement of catheters 
and by good immobility achievable with 
very short exposures. 
   Pulsed Dose Rate (PDR) treatment 
is a recent brachytherapy modality that 
combines physical advantages of high-
dose-rate (HDR) technology (isodose 
optimization, planning flexibility and ra-
diation safety) with radiobiological 
advantages of low-dose-rate (LDR) bra-
chytherapy (repair advantages).  
 
DESCRIPTION OF A METHOD 
 
   PDR was first used in San Francisco 
in 1992. There are 4 PDR microSelectrons 
in use in Poland now: in Gdańsk, Gliwice, 
Kraków and in Poznań. 
   PDR uses a single stepping 192Iridium 
source of 15-37 GBq (0,5 – 1Ci). This pro-
duces treatment dose rates of up to about 
3 Gy per hour, which can be utilized 
(pulsed) every hour, 24 pulses per day.  
   The source is enclosed in a 2,5 mm long 
capsule 1.1 mm in diameter. Treatment 
times can be programmed from 0 to 999.9 
seconds per position per pulse. The single 
radioactive stepping source moves 
through all the implanted catheters during 
each pulse. A typical pulse length lasts 
10 minutes per hour, which may be incre-
ased to approximately 30 minutes three 
month later when the 192Ir source has 
decayed.     
   Pulsed brachytherapy uses a stronger 
radiation source than that employed 
in LDR brachytherapy and gives a series 
of short 10 to 30 minute exposure long 
every hour amounting to approximately 
the same total dose in the same overall 
time as that in LDR (Fig. 1). 
 
 
Fig. 1. Illustration of the principle of pulsed brachytherapy.
A continuous low dose rate of 0,5 Gy/h is replaced by a pulse 
of 0,5 Gy delivered in 10 minutes. As a single iridium192 
source decays with the half-life of 74 days, the pulse length 
is adjusted to maintain the dose per pulse to be precisely
0,5 Gy. Thus, the average dose rate is maintained and
the overall treatment time for a given total dose remains 
fixed.
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   The trajectory of a single high activity 
source through the implanted catheter can 
be precisely programmed by a dedicated 
computer and carried out by a remote 
source projector.  
   The resulting isodoses can be optimized 
by modulating the dwell time of the source 
as a function of its trajectory within 
the implanted volume. This allows indi-
vidualization of dose distributions, while 
essentially eliminating radiation exposure 
to the medical staff.  
   The source strength is 10 to 20 times 
lower than that used in HDR, and the re-
quirements for shielding are less stringent. 
An ordinary brachytherapy room would 
require less than two extra half, value 
thickness of protection, and an accelerator 
type bunker is not necessary. 
   Nursing care is facilitated compared with 
LDR brachytherapy, since patients can be 
attended between the treatment sessions, 
without concern about problems of radio-
protection.      
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RADIOBIOLOGY OF PULSED BRACHY-
THERAPY 
 
   Gaps between pulses allow greater 
freedom for the patient and increase 
safety for nursing staff. However, in prin-
ciple, any move away from continuous 
exposure towards treatment with gaps 
involves some radiobiological disadvan-
tage. Pulsed brachytherapy is equivalent 
to fractionation with a larger dose per 
fraction, and the theoretical and expe-
rimental evidence that this procedure will 
lead to a relative increase in the late 
normal-tissue reactions is strong. The ma-
gnitude of this effect has been considered 
by Brenner and Hall, who concluded that 
for gaps between pulses of up to 60 mi-
nutes the radiobiological deficit may 
be acceptable [8].  
   In PDR brachytherapy each pulse 
delivers a small dose and is followed by 
an interval which allows some repair, 
the increase in the radiobiological effect 
being small. However, the main question 
is whether the increased effect is greater 
in late-responding normal tissues than 
in tumour cell kill.    
   To reproduce the biological effects 
of LDR brachytherapy using PDR remote 
afterloading Brenner i Hall [8] and Fowler 
i Mount [9] offer the following four re-
commendations: 
(1) same total dose, 
(2) same dose rate: typically about 
0,5 Gy/hour,  
(3) pulse length of 10 minutes or more 
(or dose rate not exceeding 3 Gy/hour 
during the pulse), and 
(4) pulse repeated each hour: typically 
0,4 - 1,0 Gy/ hour. 
   If these conditions are met, the biological 
effects of PDR radiation therapy should 
be equivalent to those of LDR radiation 
therapy for all tissues.     
   The above conclusions were drawn from 
calculations taking into account both 
the cell repair capacity (estimated 
by alpha/beta) and the kinetics of repair 
(estimated by T1/2), for tumours and late-
reacting normal tissues. The alpha/beta 
value for tumours and late reacting human 
tissues have been estimated and are 
consistent with laboratory results using 
experimental models. By contrast, due 
to the lack of clinical data, T1/2 has been 
estimated from experimental data [10].  
   However, it is likely that early-res-
ponding tissues, such as tumours, repair 
sublethal damage more rapidly than 
do late-responding tissues. In 1996, 
Brenner and Hall exploited this difference 
to design new therapeutic regimens. They 
estimated, using a T1/2 of 0,5 hours 
for early-responding tissues and 4 hours 
for late-responding, that PDR brachy-
therapy delivering series of pulses 
separated by 3-4 hours should produce 
better results than LDR brachytherapy 
[11,12,13]. 
         
Advantages of PDR 
 
(1) Full radiation protection, 
(2) No source preparation, 
(3) No source inventory, 
(4) Optimization of the dose rate distri-
bution, 
(5) Only one source to replace every 
three months, and 
(6) All brachytherapy feasible with one 
machine: intracavitary, interstitial, intra-
operative, intraluminal. 
 
Limitations of PDR 
 
   PDR treatment has a certain number 
of practical limitations:  
(1) The maximum number of needles that 
can be implanted is limited by the num-
ber of afterloading channels: 18 in ca-
se of the PDR MicroSelectron,  
(2) Only one person per day can be trea-
ted,  
(3) Another disadvantage of the system 
compared with LDR is the presence 
of connecting tubes between the ma-
chine and the needles (catheters), 
the weight of which may cause some 
discomfort to the patient, and  
(4) Finally, the multiple source transfers 
may result in treatment irregularities 
due to source blockages, particularly 
in the case of implanted plastic tubes.    
   Although the PDR approach has been 
the subject of numerous theoretical pa-
pers, and afterloading machines modified 
for PDR treatments have been co-
mmercially available for several years, 
very little data have been published 
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regarding on the clinical experience with 
these techniques.   
 
CONCLUSIONS 
 
   PDR brachytherapy offers several 
advantages over conventional LDR bra-
chytherapy: 
(1) The distribution of radiation doses can 
be more easily controlled and tailored 
permitting the following improvements: 
(a) more precise application (then 
LDR) of the prescribed dose 
to the treatment volume, 
(b) better reproducibility of treatment 
plans,  
(c) greater flexibility to change the 
dose distribution through the 
course of treatment if necessary,  
(2) Improved radiation safety for clinical 
and physics staff, 
(3) Only one source to replace every 
three months, and 
(4) All brachytherapy procedure feasible 
with one machine: intracavitary, inter-
stitial, intraoperative and intraluminal. 
Compared with HDR brachytherapy 
(1) PDR offers similar quality of treat-
ment, 
(2) Similar treatment procedure and tech-
nical verification, 
(3) Improved radiation safety for clinical 
and physics staff,  
(4) Requirements for shielding are less 
stringent - an accelerator type bunker 
is not necessary,  
(5) Theoretical radiobiological advantage: 
the technique allows some repair 
in late-reacting normal tissue due 
to intervals between pulses,  
(6) patient comfort is believed to be wor-
se, and 
(7) few indications for palliative treatment. 
   Clinical feasibility studies are in progress. 
Summarized indications and prescribed 
doses are presented in Table 1 and 2 
(Table 1, 2). 
 
Table 1. Clinical applications and proposed doses.  
 
TUMOUR 
(method of treatment) TOTAL DOSE PULSE DOSE TOTAL TIME 
1/ oesophagus: 
-palliative 
-combined with EBRT 
 
2x  16 - 20 Gy 
20 Gy 
 
0,4 - 0,6 Gy 
0,5 Gy 
 
40 - 50 h 
20 h 
2/ bronchus: 
-palliative 
-palliative (II) 
-combined with EBRT 
 
1x,2x  25 Gy 
10 - 15 Gy 
5 - 12 Gy 
 
0,5 - 0,6 Gy/0,5 h 
1 - 1,5 Gy 
0,5 - 0,6 Gy/0,5 h 
 
25 h 
10 -15 h 
5 - 10 h 
3/ gynaecology: 
-radically 
-combined with EBRT 
 
4x-5x   60 Gy 
2x   20 - 30 Gy 
 
0,4 - 0,5 Gy 
0,4 - 0,5 Gy 
 
120 - 150 h 
50 - 60 h 
4/ breast: 
-"boost" 
-combined with EBRT 
in LABC 
 
10 - 25 Gy 
20 - 30 Gy 
 
0,5 - 1,0 Gy 
0,5 - 1,0 Gy 
 
10 - 25 h 
20 - 30 h 
5/ HAN: 
-palliative 
-combined with EBRT 
 
2x  20 - 30 Gy 
2x   20 Gy 
 
0,5 Gy 
0,5 Gy 
 
40 - 60 h 
40 h 
6/ anus, rectum: 
-radically 
-combined with EBRT 
 
4-5x  60 - 70 Gy 
2x   16 - 20 Gy 
 
0,4 - 0,5 Gy 
0,4 - 0,5 Gy 
 
120 - 140 h 
40 h 
 
HAN - Head and Neck tumors 
LABC - Locally advanced breast cancer 
EBRT – External radiotherapy 
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Table 2. Indications for PDR-brachytherapy in different tumours (based on published researches). 
 
Indications 
Localization 
Radical treatment Palliative treatment 
Contrindications 
1/ Esophageal 
cancer (1, 2, 5, 6, 14) 
1st and 2nd clinical stage – patients 
disqualified from surgical treatment 
because of: 
(a) localization 
(b) medical contrindications 
(c) loss of patients consent 
Patients with: 
(1) dysphagia 
(2) in advanced age  
(3) with cachexia 
(4) with distant metastases 
(5) with recurrence after teletherapy 
(6) with progression after 
teletherapy 
(1) infiltration of cardiae
(2) broncho-esophageal 
fistula 
2/ Lung cancer 
(1, 2, 5, 14) 
(1) “boost” after teletherapy 
(2) clinical stage of T1-2 N1-2 M0 
(1) recurrence after teletherapy 
(2) patients with non squmaous cell 
cancer disqualified from radical 
teletherapy, with dyspnoea due 
to bronchial or tracheal obturation 
(1) tumour localized 
in extern part of the lung
(2) Pancoast tumour 
(3) syndrom of venae 
cavae superior 
(4) massive haemoptysis
3/ Gynecological 
tumors 
(1, 2, 15, 16, 17) 
Indications like those in LDR 
brachytherapy 
Indications like those in LDR 
brachytherapy 
 
4/ Breast cancer 
(1, 2, 18, 19) 
I. “Boost” after teletherapy 
in breast-sparing surgical 
treatment (lumpectomy, 
quadrantectomy) 
Condition: separate cutting 
for tumorectomy 
and lymphadenectomy 
(a) brachytherapy as a “boost” after 
teletherapy 
(b) brachytherapy before teletherapy 
(catheters are implanted during 
surgery) is performed two weeks after 
surgery 
II. Brachytherapy connected with 
teletherapy in local advanced 
breast cancer (excluding T4) 
Patients previously treated with 
chemotherapy, disqualified 
for surgery 
 Localization of tumour
at a shorter distance 
than 1 cm from skin 
surface or ribbs 
- excluding ductal 
carcinoma “in situ” 
- in this case treatment 
plan should include 
papilla and areola 
of the mamma 
5/ HAN tumours 
(1, 2, 20, 21, 22) 
(1) radical, independent treatment 
(2) complementary treatment after 
non radical surgical treatment 
(3) “boost” after teletherapy 
(1) palliative treatment 
of recurrence after teletherapy 
 
6/ Rectal, anal 
cancer 
(1, 2, 23, 24, 25) 
(1) Clinical stage – T1, T2 i N0 – 
brachytherapy optionally to surgery
(2) in more advanced tumours – 
combined treatment: 
chemotherapy (5-Fu, Mitomycyna C) 
+ teletherapy (40 – 50 Gy), then 
brachytherapy after two months 
interval (due to slow regression of 
tumour and necrosis prophylaxis) 
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